PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 14, 2026Physiology0 citations

An untargeted metabolic profiling of myocardium and serum in patients with left ventricular assist devices

View Full Paper
VLVilija LomeikaiteNANadia AshrafiKKKarolis Krinickis

Key Points

  • This study aims to characterize metabolic signatures in patients with end-stage heart failure receiving LVAD support.
  • Paired serum and myocardial tissue samples collected from 12 patients at LVAD implantation and heart transplantation.
  • Untargeted liquid chromatography-mass spectrometry (LC-MS) used for global metabolic profiling.
  • Differential abundance analysis identified significant metabolite changes, excluding pharmaceutical metabolites.
  • Myocardial tissue showed decreased adenosine-5-diphosphate levels (logFC -0.58, FDR q < 0.05) and octanoic acid (logFC -0.32, FDR q < 0.05).
  • Increased androsterone glucuronide (logFC 1.44, FDR q < 0.05) and estrone (logFC 0.9, FDR q < 0.05) levels noted post-LVAD support.
  • Serum showed reduced pyruvic acid levels (logFC -0.65, FDR q < 0.05), indicating improved peripheral perfusion.

Abstract

Background: Mechanical unloading via left ventricular assist devices (LVADs) is an established therapy for end-stage heart failure (ESHF). Although LVAD support improves hemodynamics and can promote structural reverse remodeling, the accompanying metabolic changes within the myocardium and systemic circulation remain insufficiently defined. The objective of this study was to describe metabolic signatures associated with LVAD support in ESHF using an unbiased, untargeted profiling approach. Methods: Paired serum (N = 8) and myocardial tissue (N = 12) samples were collected from ESHF patients at two timepoints: at LVAD implantation and at heart transplantation. Global metabolic profiling was conducted using untargeted liquid chromatography-mass spectrometry (LC-MS). Differential abundance analysis was carried out to identify metabolites with significant changes between time points, with filtering applied to exclude pharmaceutical metabolites and metabolites lacking annotations. Results: In myocardial tissue, LVAD support was associated with lower levels of adenosine-5-diphosphate (logFC -0.58, FDR q < 0.05) and octanoic acid (logFC -0.32, FDR q < 0.05), metabolites related to cellular energetics and fatty acid oxidation pathways. In contrast, androsterone glucuronide (logFC 1.44, FDR q < 0.05) and estrone (logFC 0.9, FDR q < 0.05) increased following LVAD support, indicating shifts in steroid-related metabolic pathways. Serum profiles differed from tissue findings and were characterized primarily by reduced pyruvic acid levels (logFC -0.65, FDR q < 0.05) post-LVAD support, consistent with a reduction in systemic anaerobic glycolysis and improved peripheral perfusion. Conclusion: We show that LVAD support is accompanied by measurable tissue-specific metabolic differences. While systemic changes appear to reflect the clearance of glycolytic byproducts due to improved perfusion, the myocardium is characterized by changes in energetic substrates and steroid metabolites. These findings suggest that mechanical unloading may facilitate a re-regulation of cardiomyocyte metabolism, offering further insight into the physiology of reverse remodeling. This abstract was presented at the American Physiology Summit 2026 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Lomeikaite et al. (2026) studied this question.

synapsesocial.com/papers/6a05684ea550a87e60a20be1https://doi.org/10.1152/physiol.2026.41.s1.2300620
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Analysis of Metabolic Markers in Patients with Chronic Heart Failure before and after LVAD Implantation2021 · 6 citations
  2. 2LVAD or no LVAD: biomechanical signatures of mechanical unloading2026
  3. 3Comparison of Right and Left Ventricular Responses to Left Ventricular Assist Device Support in Patients With Severe Heart Failure2001 · 224 citations
  4. 4Left Ventricular Assist Device Effects on Metabolic Substrates in the Failing Heart2013 · 22 citations
  5. 5Proteomics highlights decrease of matricellular proteins in left ventricular assist device therapy†2017 · 20 citations